pan-genotype HCV NS3/4A protease inhibitor
proj. oral QD dosing, well-tolerated in rodent
deuteration reduced CYP TDI
J. Med. Chem., Nov. 23, 2020
Bristol-Myers Squibb, NJ + MA + CT + IN
BMS-986144
1 min read
Bristol-Myers Squibb (BMS) pan-genotype HCV NS3/4A protease inhibitor
Search By Structure
- LY3502970
- S64315
- daridorexant
- “peptide 78”
- BMS-986144
- MLT-985
- EB-42486
- “compound 4d”
- “compound 60b”
- “compound 15a”
- “compound 31”
- “compound 36”
- BCPyr
- “compound 4j”
Molecules of the Month
2023
2022
2021
2020